medigraphic.com
Instituto Nacional de Neurología y Neurocirugía

2023, Number 2

<< Back Next >>

Arch Neurocien 2023; 28 (2)

Therapeutic potential of cannabinoids for stroke: scoping review protocol

Pérez-Neri I, Estêvão MD, Mishra R, Sandoval H, Zárate M, Ríos C

Language: English
References: 39
Page: 28-34
PDF size: 240.72 Kb.


ABSTRACT

Introduction: Each year, approximately 795,000 people experience a new or recurrent stroke, ischemic or hemorrhagic. The current therapeutical approach for acute ischemic stroke includes thrombolysis and mechanical thrombectomy. However, there are no neuroprotective treatment alternatives to improve its neurological outcome. Some components of the endocannabinoid system are altered after ischemic stroke. Cannabinoids may exert neuroprotective effects, but the use of cannabinoid receptor ligands is a factor to consider due to their psychotropic properties. Regardless of the various studies describing the benefit of administering cannabinoids for experimental stroke, several questions remain unanswered since most information is about non-human species. A previous systematic review detected significant heterogeneity among studies, therefore a scoping review was performed to evaluate the feasibility of an updated systematic review and meta-analysis. This scoping review protocol aims to evaluate the therapeutic potential of modulating the endocannabinoid system for stroke. Methods: Published studies (all publication types) will be retrieved from Web of Science, PubMed, Scopus, Ovid, EBSCOhost, and Google Scholar. Eligibility criteria: Clinical or preclinical studies reporting endocannabinoid levels or their effects, or reporting administration of cannabinoid modulators (stimulating or inhibiting their synthesis or metabolism, phytocannabinoids, or synthetic cannabinoids) in patients or models of stroke will be considered for inclusion. Studies written in languages different than Spanish or English that could not be properly translated or whose full-text files could not be retrieved will be excluded. Data charting: Results will be summarized in tabular form. This protocol complies with PRISMA-P.


REFERENCES

  1. United Nations Office on Drugs and Crime. World Drug Report 2021. United Nations publication, Sales No. E.21.XI.8; 2021.doi: 10.18356/9789210058032

  2. Tournebize J, Gibaja V, Kahn JP. Acute effects of syntheticcannabinoids: Update 2015. Subst Abus. 2017;38(3):344-66.

  3. Virani SS, Alonso A, Aparicio HJ, Benjamin EJ, Bittencourt MS,Callaway CW, et al. Heart disease and stroke statistics-2021update: A report from the American Heart Association.Circulation. 2021;143(8):e254-e743.doi:10.1161/CIR.0000000000000950

  4. Nelson S, Whitsel L, Khavjou O, Phelps D, Leib A. Projections ofcardiovascular disease prevalence and costs: 2015–2035. RTIInternational; 2016.

  5. Stewart C, Subbarayan S, Paton P, Gemmell E, Abraha I, Myint PK,et al. Non-pharmacological interventions for the improvementof post-stroke quality of life amongst older stroke survivors:a systematic review of systematic reviews. Eur Geriatr Med.2019;10(3):359-86. doi: 10.1007/s41999-019-00180-6

  6. Zarruk JG, Fernández-López D, García-Yébenes I, García-Gutiérrez MS, Vivancos J, Nombela F, et al. Cannabinoid type2 receptor activation downregulates stroke-induced classic andalternative brain macrophage/microglial activation concomitantto neuroprotection. Stroke. 2012;43(1):211-9. doi: 10.1161/STROKEAHA.111.631044

  7. Jouanjus E, Raymond V, Lapeyre-Mestre M, Wolff V. What is thecurrent knowledge about the cardiovascular risk for users ofcannabis-based products? A systematic review. Curr AtherosclerRep. 2017;19(6):26. doi: 10.1007/s11883-017-0663-0

  8. Yoo SGK, Seth M, Vaduganathan M, Ruwende C, Karve M,Shah I, et al. Marijuana use and in-hospital outcomes afterpercutaneous coronary intervention in Michigan, UnitedStates. JACC Cardiovasc Interv. 2021;14(16):1757-67. doi:10.1016/j.jcin.2021.06.036

  9. Gómez Ochoa SA. Stroke and cannabis use in patients with nocardiovascular risk factors: a systematic review of case reports.Neurologia (Engl Ed). 2021;36(3):222-8. doi: 10.1016/j.nrl.2017.09.016

  10. Chiu RG, Fuentes AM, Patil SN, Chiu R, McGuire LS, MehtaAI. Cannabis abuse and perioperative complications aftertreatment of intracranial aneurysms: A nationwide analysis.World Neurosurg. 2022 Feb;158:e184-e195. doi: 10.1016/j.wneu.2021.10.156

  11. Rabat Y, Sibon I, Berthoz S. Implication of problematic substanceuse in poststroke depression: An hospital-based study. Sci Rep.2021;11(1):13324. doi: 10.1038/s41598-021-92639-5

  12. Gorelick DA, Hermann R. Cannabis use and disorder:Epidemiology, comorbidity, health consequences, and medicolegalstatus. UpToDate. 2020; 20172-150:1-36.

  13. England TJ, Hind WH, Rasid NA, O’Sullivan SE. Cannabinoidsin experimental stroke: A systematic review and meta-analysis. JCereb Blood Flow Metab. 2015;35(3):348-58. doi: 10.1038/jcbfm.2014.218

  14. Marinelli L, Balestrino M, Mori L, Puce L, Rosa GM, GiorelloL, et al. A randomised controlled cross-over double-blindpilot study protocol on THC: CBD oromucosal spray efficacyas an add-on therapy for post-stroke spasticity. BMJ open.2017;7(9):e016843. DOI: 10.1136/bmjopen-2017-016843

  15. Moser U. Tetrahydrocannabinol and cannabidiol as anoromucosal spray in a 1: 1 ratio: a therapeutic option for patientswith central post-stroke pain syndrome. BMJ Case Reports CP.2021;14(7):e243072. doi: 10.1136/bcr-2021-243072

  16. Hashiesh HM, Jha NK, Sharma C, Gupta PK, Jha SK, Patil CR, etal. Pharmacological potential of JWH133, a cannabinoid type 2receptor agonist in neurodegenerative, neurodevelopmental andneuropsychiatric diseases. Eur J Pharmacol. 2021;909:174398.

  17. Sultan SR, Millar SA, England TJ, O’Sullivan SE. A systematicreview and meta-analysis of the haemodynamic effects ofcannabidiol. Front Pharmacol. 2017;8:81. doi: 10.3389/fphar.2017.00081

  18. Wang LN, Xing MD, Qu WT, Wang CB, Liu ZQ, Han J, et al.Impaired vessel relaxation response and increased infarct size insmooth muscle cannabinoid receptor 1 knockout mice. MicrovascRes. 2022;139:104263. doi: 10.1016/j.mvr.2021.104263

  19. Davis MP, Behm B, Mehta Z, Fernandez C. The Potential Benefitsof Palmitoylethanolamide in Palliation: A Qualitative SystematicReview. Am J Hosp Palliat Care. 2019;36(12):1134-54. doi:10.1177/1049909119850807

  20. Annunziata C, Pirozzi C, Lama A, Senzacqua M, Comella F,Bordin A, et al. Palmitoylethanolamide promotes white-tobeigeconversion and metabolic reprogramming of adipocytes:Contribution of PPAR-α. Pharmaceutics. 2022;14(2):338. doi:10.3390/pharmaceutics14020338

  21. Azar S, Udi S, Drori A, Hadar R, Nemirovski A, Vemuri KV, etal. Reversal of diet-induced hepatic steatosis by peripheral CB1receptor blockade in mice is p53/miRNA-22/SIRT1/PPARαdependent. Mol Metab. 2020;42:101087.

  22. Pérez-Neri I, Diéguez-Campaa CE, Sandoval H, ChávezVA, Castro-Martínez E, Ríos C. Therapeutic potential ofdehydroepiandrosterone for Parkinson’s disease: scoping reviewprotocol. Arch Neurocien. 2022;27(2):39-46. doi: 10.31157/an.v27i2.331

  23. Rosca EC, Tudor R, Cornea A, Simu M. Parkinson’s disease inRomania: A scoping review protocol. Brain Sci. 2021;11(2):251.

  24. Polhemus AM, Bergquist R, Bosch de Basea M, Brittain G,Buttery SC, Chynkiamis N, et al. Walking-related digital mobilityoutcomes as clinical trial endpoint measures: protocol fora scoping review. BMJ Open. 2020;10(7):e038704. doi:10.1136/bmjopen-2020-038704.

  25. Aromataris E, Munn Z, editors. JBI Manual for Evidence Synthesis.JBI; 2020.

  26. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, MulrowCD, et al. PRISMA 2020 explanation and elaboration: Updatedguidance and exemplars for reporting systematic reviews. BMJ.2021;372:n160. doi: 10.1136/bmj.n160

  27. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H,Chalmers I, et al. PRISMA for Abstracts: reporting systematicreviews in journal and conference abstracts. PLoS Med.2013;10(4):e1001419. doi: 10.1371/journal.pmed.1001419

  28. Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, PetticrewM, et al. Preferred reporting items for systematic review andmeta-analysis protocols (PRISMA-P) 2015: elaboration andexplanation. BMJ. 2015;350:g7647. doi: 10.1136/bmj.g7647

  29. Rethlefsen ML, Kirtley S, Waffenschmidt S, Ayala AP, Moher D,Page MJ, et al. PRISMA-S: an extension to the PRISMA Statementfor Reporting Literature Searches in Systematic Reviews. Syst Rev.2021;10(1):39. doi: 10.1186/s13643-020-01542-z.

  30. Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for Scoping Reviews (PRISMA-ScR): checklist andexplanation. Ann Intern Med. 2018;169(7):467-73. doi: 10.7326/M18-0850

  31. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studiesreporting prevalence and cumulative incidence data. Int J Evid Based Healthc. 2015;13(3):147-53. doi: 10.1097/XEB.0000000000000054

  32. McGowan J, Sampson M, Salzwedel DM, Cogo E, Foerster V, Lefebvre C. PRESS Peer Review of Electronic Search Strategies: 2015Guideline Statement. J Clin Epidemiol. 2016;75:40-6. doi: 10.1016/j.jclinepi.2016.01.021

  33. Bramer WM, de Jonge GB. Improving efficiency and confidence in systematic literature searching. Workshop given at InternationalCongress of Medical Librarianship (ICML) & European Association for Health Information and Libraries (EAHIL). Dublin; 2017:1-16.

  34. Willcox MDP, Walsh K, Nichols JJ, Morgan PB, Jones LW. The ocular surface, coronaviruses and COVID -19. Clin Exp Optom.2020;103(4):418-44. doi: 10.1111/cxo.13088

  35. Pérez-Neri I, González-Aguilar A, Sandoval H, Pineda C, Ríos C. Therapeutic potential of ultrasound neuromodulation in decreasingneuropathic pain: Clinical and experimental evidence. Curr Neuropharmacol. 2021;19(3):334-48. doi: 10.2174/1570159X18666200720175253

  36. McKeown S, Mir ZM. Considerations for conducting systematic reviews: evaluating the performance of different methods for de-duplicatingreferences. Syst Rev. 2021;10(1):38. doi: 10.1186/s13643-021-01583-y

  37. Bozada T, Borden J, Workman J, Del Cid M, Malinowski J, Luechtefeld T. Sysrev: A FAIR platform for data curation and systematic evidencereview. Front Artif Intell. 2021;4:685298. doi: 10.3389/frai.2021.685298

  38. Garritty C, Gartlehner G, Nussbaumer-Streit B, King VJ, Hamel C, Kamel C, et al. Cochrane Rapid Reviews Methods Group offersevidence-informed guidance to conduct rapid reviews. J Clin Epidemiol. 2021;130:13-22. doi: 10.1016/j.jclinepi.2020.10.007

  39. Usher R, Stapleton T. Approaches for assessing decision-making capacity in older adults: a scoping review protocol. JBI Evidence Synthesis.2020;18(4):832-40. doi: 10.11124/JBISRIR-D-19-00068




2020     |     www.medigraphic.com